FN2 Earnings Intelligence
Eli Lilly and Company financials
Eli Lilly and Company (LLY) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $3,818.5 | $2,067 | $2,818.6 | $3,268.4 | $7,268 | - | - |
| + Debt | $16,884.7 | $16,238.6 | $25,225.3 | $33,644.2 | $42,503 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $28,318.4 | $28,541.4 | $34,124.1 | $45,042.7 | $65,179 | $85,275.5 | $99,316.4 |
| % Growth | 15.4% | 0.8% | 19.6% | 32.0% | 44.7% | 30.8% | 16.5% |
| Gross Profit | $21,005.6 | $21,911.6 | $27,041.9 | $36,624.4 | $54,127 | - | - |
| % Margin | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% | - | - |
| EBITDA | - | - | - | - | - | - | - |
| % Margin | - | - | - | - | - | - | - |
| Net Income | $5,581.7 | $6,244.8 | $5,240.4 | $10,590 | $20,640 | - | - |
| % Margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% | - | - |
| Diluted EPS | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 | $35.12 | $45.20 |
| % Growth | -9.9% | 12.7% | -15.9% | 101.9% | 96.0% | 53.0% | 28.7% |
| Operating Cash Flow | $7,260.7 | $7,084.4 | $4,240.1 | $8,817.9 | $16,813 | - | - |
| CapEx | $1,309.8 | $1,854.3 | $3,447.6 | $5,057.8 | $7,841 | - | - |
| Free Cash Flow | $5,950.9 | $5,230.1 | $792.5 | $3,760.1 | $8,972 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $28,318.4 | $28,541.4 | $34,124.1 | $45,042.7 | $65,179 | $85,275.5 | $99,316.4 |
| Gross Profit | $21,005.6 | $21,911.6 | $27,041.9 | $36,624.4 | $54,127 | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Net Income | $5,581.7 | $6,244.8 | $5,240.4 | $10,590 | $20,640 | - | - |
| Diluted EPS | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 | $35.12 | $45.20 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3,818.5 | $2,067 | $2,818.6 | $3,268.4 | $7,268 |
| Short-term Debt | $1,538.3 | $1,501.1 | $6,904.5 | $5,117.1 | $1,635 |
| Long-term Debt | $15,346.4 | $14,737.5 | $18,320.8 | $28,527.1 | $40,868 |
| Total Debt | $16,884.7 | $16,238.6 | $25,225.3 | $33,644.2 | $42,503 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7,260.7 | $7,084.4 | $4,240.1 | $8,817.9 | $16,813 |
| Capital Expenditure | $1,309.8 | $1,854.3 | $3,447.6 | $5,057.8 | $7,841 |
| Free Cash Flow | $5,950.9 | $5,230.1 | $792.5 | $3,760.1 | $8,972 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 15.4% | 0.8% | 19.6% | 32.0% | 44.7% |
| Gross Margin | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% |
| EBITDA Margin | - | - | - | - | - |
| Net Margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| FCF Margin | 21.0% | 18.3% | 2.3% | 8.3% | 13.8% |
| Diluted EPS Growth | -9.9% | 12.7% | -15.9% | 101.9% | 96.0% |